QDEL · QuidelOrtho Corp
$15.32
+0.41 (+2.72%)
At close · Aug 27
Market Cap
$1.02B
Shares
68.58M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$14.91
Open$15.09
Day$14.55–15.09
52W close$9.96–35.38
Avg vol 30d1.5M
Short int15.0M · 21.8% float · 7.6d
Short vol50%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 7
Up next
Next earnings call
Nov 7, 2026
Est · unconfirmed
· in 10 wks
FQ3-27 quarter ends
~Oct 1, 2026
Est
filed Aug 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−24%
below
Price vs 50-day avg
−6%
below
RSI (14)
48
neutral
MACD trend
Positive
52-week position
19%
mid-range
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−30%
trailing
YTD return
−48%
this year
Relative strength
−43%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $16 › 200d $20 — 200d above 50d
Institutional flow
Accumulating
+2% holders QoQ · +59 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
21.82% of float · ▲ +15.0% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
247 holders — near 3-yr low, contrarian setup
Squeeze score
72
high risk · 0–100
Fundamentals
Revenue growth
−2%
Y/Y
EPS growth
+45%
Y/Y
Free cash flow
$-83.0M
Buyback
$218.4M
remaining
Balance sheet
$2.5B
net debt
Quant / Vol
risk profile
Volatility
89%
annualized · 1-yr
Max drawdown
−72%
past year
ATR
8.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
Total revenues (reported)
· Full-year 2026
Lowered
$2.52B – $2.6B
May 5, 2026
$2.7B – $2.75B
changed to
Aug 6, 2026
$2.52B – $2.6B
prior FY $2.73B
midpoint −6.2% Y/Y
Adjusted EBITDA
· Full-year 2026
Non-GAAP
Lowered
$540M – $560M
May 5, 2026
$615M – $630M
changed to
Aug 6, 2026
$540M – $560M
Adjusted EBITDA margin
· Full-year 2026
Non-GAAP
Lowered
21% – 22%
May 5, 2026
23%
changed to
Aug 6, 2026
21% – 22%
Adjusted diluted EPS
· Full-year 2026
Non-GAAP
Initiated
$0.65 – $0.90
Prior guidance
period ended
· from the 8-K filed Apr 15, 2026
Preliminary unaudited revenue, as reported
· first quarter of 2026
$615M – $620M
Guided vs delivered
· last 3 settled
Full year 2025 total reported revenue
full year 2025
guided $2.68B – $2.74B
$2.73B
In line
Full year 2024 total reported revenues
full year 2024
guided $2.75B – $2.8B
$2.78B
In line
Total revenue
fiscal '23 full-year
guided $2.88B – $3.08B
$3B
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−24%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
48
Neutral
MACD trend
Positive
Bullish
52-week position
19%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $16 › 200d $20 — 200d above 50d
Institutional flow
Accumulating
+2% holders QoQ · +59 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
21.82% of float · ▲ +15.0% MoM · 7.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
247 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $10
Now $15 · 19%
Range high $35
vs 200-day avg -24%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Total segment Adjusted EBITDA non-GAAP | $260M | Three Months Ended June 28, 2026 filing | +0.8% |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Total segment Adjusted EBITDA $260M
-$130.7M Corporate
-$116.7M Depreciation and amortization
-$54.7M Interest expense, net
-$6.5M Restructuring, integration and other charges
-$9.2M Amortization of deferred cloud computing implementation costs
-$4.5M Employee compensation charges
-$3.3M Tax indemnification expense
-$0.7M EU medical device regulation transition costs
-$8.1M Loss on investments
-$6.8M Other adjustments
= Total segment Adjusted EBITDA -$81.2M
|
|||
| Adjusted diluted EPS non-GAAP | $0.1 | Six Months Ended June 28, 2026 | — |
|
|
|||
| Adjusted EBITDA non-GAAP | 238M | Six Months Ended June 28, 2026 | — |
|
|
|||
| adjusted EBITDA margin non-GAAP | 20.5% | Q2 2026 | — |
|
|
|||
| Adjusted net income non-GAAP | 6.8M | Six Months Ended June 28, 2026 | — |
| Free cash flow non-GAAP | -$76.5M | FY 2025 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities $105.2M
-$188.2M Acquisitions of property, plant, equipment, investments and intangibles
+$6.5M Proceeds from government assistance allocated to fixed assets
= Free cash flow -$76.5M
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QDEL
this stock
QuidelOrtho Corp
|
$1.02B | -47.8% | -1.9% | — | 21.8% |
|
ABT
Abbott Laboratories
|
$198.74B | -8.9% | +5.7% | 32.0 | 1.2% |
|
SYK
Stryker Corp
|
$126.45B | -6.2% | +11.2% | 34.2 | 1.8% |
|
MDT
Medtronic plc
|
$117.57B | -4.2% | +8.4% | 24.6 | 1.1% |
|
BSX
Boston Scientific Corp
|
$68.44B | -49.5% | +12.5% | 19.1 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QDEL | +8.0% | -9.6% | -30.4% | -11.1% | -47.8% |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | +8.4% | -14.7% | -42.8% | -13.6% | -60.1% |
Capital returns
Buyback program
· as of Dec 31, 2023
Authorized
$300.00M
Spent (derived)
$81.60M
Remaining
$218.40M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1906324
CUSIP
219798105
13F (30d)
200 filings
196 filers
Visit website
Investor relations